MedDataX Logo

Magnesium and Dexmedetomidine in Pheochromocytoma

NCT ID: NCT05102058

Last Updated: 2021-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

108 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-01

Study Completion Date

2020-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration between the group treated with magnesium-dexmedetomidine and conventional group in pheochromocytoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Phaeochromocytoma Crisis Hemodynamic Instability

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Magnesium Dexmedetomidine Nitroprusside Pheochromocytoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional group (GC)

Not receive perioperative additional medication.

No interventions assigned to this group

Magnesium-dexmedetomidine therapy group (GMD)

Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively.

Magnesium-Dexmedetomidine

Intervention Type DRUG

Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium-Dexmedetomidine

Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anesthesiologists classification (ASA) 1-3
* high urinary catecholamine or metabolites
* tumor sizes \< 5 cm
* body mass index (BMI) \<35 kg/m2

Exclusion Criteria

* open surgery
* bilateral masses
* tumor larger than 5 cm
* incomplete data
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istanbul University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nukhet Sivrikoz

Attending Anesthesiologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nükhet Sivrikoz, MD

Role: PRINCIPAL_INVESTIGATOR

Attending anesthesiologist

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021/42

Identifier Type: -

Identifier Source: org_study_id